Plus Therapeutics to Present New REYOBIQ™ Clinical Data at Nuclear Medicine Symposium 2025
We’re excited to announce that Plus Therapeutics will present new data on our lead radiotherapeutic compound, REYOBIQ™ (rhenium Re186 obisbemeda), at the upcoming Nuclear Medicine Symposium (NMN) 2025, taking place May 9–10, 2025, in Vienna, Austria.
This latest data will be featured in both an oral presentation and a scientific poster session, highlighting important findings related to the safety, efficacy, and clinical progress of REYOBIQ™, which is being developed for the treatment of leptomeningeal metastases (LM).
📢 Read the Press Release: https://bit.ly/3G7cVhn
📄 View the Abstract (Page 82): https://bit.ly/3GaEqXj
This presentation marks a key milestone for Plus Therapeutics, as we continue to validate our targeted radiotherapeutic platform and move REYOBIQ™ through clinical development with the support of leading research institutions and government agencies.
Stay tuned for more updates as we continue to advance precision radiotherapy solutions for hard-to-treat cancers.
#REYOBIQ #Rhenium186Obisbemeda #Radiotherapeutics #NMNSymposium2025 #Glioblastoma #LeptomeningealMetastases #PediatricBrainCancer #NuclearMedicine #CancerResearch #OncologyInnovation #ClinicalData #PlusTherapeutics
Recent Comments